The World Antibacterial Treatments Market 2010-2024

646 views

Published on

How will antibacterial treatments perform commercially' Our new pharma report examines this fundamental but increasingly-important marketOver 130 tables, charts, graphs, figures included.Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecasts for leading products in that sector. The global anti-infectives market generated revenues of $79bn for the 12 months to the second-quarter of 2009, of which the antibacterial market accounted for $37bn. How will this market perform from 2010 onwards' Our original forecasts and qualitative analyses will show you how the antibacterial sector will fare, pointing out the most-exciting and fast-growing areas.This market segment contained three blockbuster drugs in 2009: J&J's Levaquin, Tazocin from Wyeth and Pfizer's Zyvox. However, the market for antibacterial treatments is entering a crucial phase, with important brands facing patent expiry or having already past that mark, with ensuing generic competition. How is the industry dealing with this combined threat and opportunity' What will happen in future years' The World Antibacterial Treatments Market 2010-2024 explains.The market for systemic antibiotics is set to become increasingly dynamic over the forecast period (2010-2024). The key factors influencing this market segment include:' Aging populations' Increased infection rates in both developed and developing nations' Increasing bacterial resistance' Increasing numbers of immuno-compromised patients' Increases in organ transplantation.This report will specifically analyse world markets for the following classes of antibacterial agent:' Cephalosporins' Penicillins' Fluoroquinolones' Macrolides' Carbapenems' Miscellaneous agents (including tetracyclines, aminoglycosides, glycopeptides and sulphonamides).There are many infection-related disorders and cross links with other disease areas. Some infections will become increasingly challenging to treat, with a growing number of pathogens becoming resistant to existing therapies. Current R&D - including new classes of antibiotics - offers promise for the development of safer, more-effective and affordable treatments. This report will provide you with valuable information there.Detailed analysis of the world antibacterial treatments marketThe World Antibacterial Treatments Market 2010-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 130 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.Research interviews from our surveyThis report contains full original interviews with the following relevant experts:1) Dr John Philpott-Howard, Consultant Physician & Senior Lecturer in Medical Microbiology, Sub-Dean for Undergraduate Medicine, King's College London School of Medicine, UK2) Dr Eileen C. McIntyre, Cubist Pharmaceuticals Inc., Lexington, MA, USAWhy you should buy The World Antibacterial Treatments Market 2010-2024In this new report, you will receive the following benefits in particular:' You will assess the value of the world antibacterial treatments market and its principal market segments from 2009 to 2024' You will understand commercial prospects for the leading products, with sales forecasts from 2009 to 2024 and detailed discussions' Your will see the potential for generic penetration into the market from 2009 to 2024' You will see which marketed drugs have the potential to become blockbusters from 2009 to 2024.' You will review the most-exciting pipeline developments in the sector' You will receive discussion of unmet therapeutic needs

Published in: Business, Economy & Finance
  • Be the first to comment

The World Antibacterial Treatments Market 2010-2024

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!The World Antibacterial Treatments Market 2010-2024Published on December 2009 Report SummaryHow will antibacterial treatments perform commercially Our new pharma report examines this fundamental but increasingly-importantmarketOver 130 tables, charts, graphs, figures included.Our latest report examines the prospects for antibacterial treatments worldwide from 2009 to 2024, including detailed sales forecastsfor leading products in that sector. The global anti-infectives market generated revenues of $79bn for the 12 months to thesecond-quarter of 2009, of which the antibacterial market accounted for $37bn. How will this market perform from 2010 onwards Ouroriginal forecasts and qualitative analyses will show you how the antibacterial sector will fare, pointing out the most-exciting andfast-growing areas.This market segment contained three blockbuster drugs in 2009: J&Js Levaquin, Tazocin from Wyeth and Pfizers Zyvox. However,the market for antibacterial treatments is entering a crucial phase, with important brands facing patent expiry or having already pastthat mark, with ensuing generic competition. How is the industry dealing with this combined threat and opportunity What will happenin future years The World Antibacterial Treatments Market 2010-2024 explains.The market for systemic antibiotics is set to become increasingly dynamic over the forecast period (2010-2024). The key factorsinfluencing this market segment include: Aging populations Increased infection rates in both developed and developing nations Increasing bacterial resistance Increasing numbers of immuno-compromised patients Increases in organ transplantation.This report will specifically analyse world markets for the following classes of antibacterial agent: Cephalosporins Penicillins Fluoroquinolones Macrolides Carbapenems Miscellaneous agents (including tetracyclines, aminoglycosides, glycopeptides and sulphonamides).There are many infection-related disorders and cross links with other disease areas. Some infections will become increasinglychallenging to treat, with a growing number of pathogens becoming resistant to existing therapies. Current R&D - including newclasses of antibiotics - offers promise for the development of safer, more-effective and affordable treatments. This report will provideyou with valuable information there.Detailed analysis of the world antibacterial treatments marketThe World Antibacterial Treatments Market 2010-2024 examines that sector critically, through a comprehensive review of informationsources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipelineThe World Antibacterial Treatments Market 2010-2024 Page 1/12
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statisticsdevelopments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 130 tables and figuresincluded, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study,with detailed analyses and informed opinion to benefit your work.Research interviews from our surveyThis report contains full original interviews with the following relevant experts:1) Dr John Philpott-Howard, Consultant Physician & Senior Lecturer in Medical Microbiology, Sub-Dean for Undergraduate Medicine,Kings College London School of Medicine, UK2) Dr Eileen C. McIntyre, Cubist Pharmaceuticals Inc., Lexington, MA, USAWhy you should buy The World Antibacterial Treatments Market 2010-2024In this new report, you will receive the following benefits in particular: You will assess the value of the world antibacterial treatments market and its principal market segments from 2009 to 2024 You will understand commercial prospects for the leading products, with sales forecasts from 2009 to 2024 and detailed discussions Your will see the potential for generic penetration into the market from 2009 to 2024 You will see which marketed drugs have the potential to become blockbusters from 2009 to 2024. You will review the most-exciting pipeline developments in the sector You will receive discussion of unmet therapeutic needs in the antibacterial treatments market You will examine commercial drivers and restraints, with comprehensive SWOT analysis You will receive data for leading companies, including market shares You will discover views of relevant experts, including their vision for the future of the antibacterial treatments market.You can obtain this report todayNobody with an interest in the antibacterial treatments market should overlook this new study. We predict that total revenues willincrease throughout our forecast period, 2010 to 2024. With rising disease prevalence, expanding patient populations and unmetneeds, this therapeutic area holds significant potential for technological developments and revenue growth. You can stay ahead byordering this report today. Table of ContentTable of Contents1. Executive Summary1.1 Market Review: Growth to 2024 Will Be Strong1.2 Cephalosporins Class Leads the Market1.3 Aims, Scope and Format of the Report1.4 Research Methods2. Introduction to Bacterial Infections and Their Treatment2.1 Bacteria: An Introduction2.1.1 Bacterial Classification2.1.2 What is Bacterial Infection2.1.3 Bacterial Invasiveness2.1.4 Bacterial ToxigenicityThe World Antibacterial Treatments Market 2010-2024 Page 2/12
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics2.1.5 Bacterial Virulence2.1.6 The Factors that Govern the Transmission of Bacterial Disease2.1.7 Clinically-Important Bacteria2.2 Bacterial Disease Statistics2.2.1 Infectious Diseases - Major Cause of Deaths Worldwide2.2.2 Risk Factors for Bacterial Infections2.2.3 Re-emergence of Infectious Diseases A Major Global Threat2.3 Definition of Antibacterials2.4 The History of Antibacterials2.4.1 The Discovery of Penicillin2.4.2 Early Use of Penicillin2.4.3 Penicillin Resistance2.4.4 Discovery of Streptomycin, Chloramphenicol & Tetracycline2.4.5 Antibacterial Effects2.5 The Principal Mechanisms of Action for Antibacterials2.5.1 Antibacterials as Cell Wall Synthesis Inhibitors2.5.2 Antibacterials as Cell Membrane Inhibitors2.5.3 Antibacterials as Protein Synthesis Inhibitors2.5.4 The Effects of Antibacterials on Nucleic Acids2.5.5 Antibiotics as Competitive Inhibitors2.6 Antibacterial Classification by Chemical Structure2.6.1 Penicillin2.6.2 Semi-synthetic Penicillins2.6.3 Carbapenems2.6.4 Cephalosporins2.6.5 Quinolones and Fluoroquinolones2.6.6 Tetracyclines2.6.7 Aminoglycosides2.6.8 Sulphonamides2.6.9 Macrolides2.6.10 Glycopeptides2.6.11 Oxazolidinones2.7 Broad-Spectrum and Narrow-Spectrum Antibacterials3. The World Market for Antibacterials 2009-20243.1 The Global Anti-Infectives Market 20093.2 The Worldwide Anti-Bacterial Drug Market3.3 Cephalosporins: Current Market Leaders3.4 Highly Fragmented Antibacterials Market3.5 Will Cephalosporins Continue Their Domination of the Market3.6 Miscellaneous Class Will Display High Revenues from 2009 to 20243.7 Levaquin is Currently the Worlds Leading Antibacterial Agent - But will it Last3.8 Patent Expiry Will Slow Growth Rates3.9 Prescriptions for Antibiotics in the Developed World Are Falling3.10 Pharmaceutical Companies Accept that Future Antibacterial Blockbuster Drugs Will Be Increasingly Rare3.11 Generic Drugs Are Not Necessarily Cheap3.12 Competition in the Antibacterials Drug Market to Become Increasingly Intense4. The World Market for Cephalosporins, 2009-20244.1 An OverviewThe World Antibacterial Treatments Market 2010-2024 Page 3/12
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics4.2 Cephalosporins Will Suffer from Patent Expiration4.3 Rocephin is Current Leader in the Cephalosporins Market4.4 Rocephin Will Further Decline in Growth4.4.1 Rocephins Eroding Market Share Due to Generic Competition4.5 Shionogis Flomox is the Second-Leading Cephalosporin4.6 Zinnat (GSK) - the Third-Leading Cephalosporin Worldwide4.7 Leading Pharmaceutical Companies in the Cephalosporin Class4.8 Cephalosporin Sales by Region5. The World Market for Broad Spectrum Penicillins, 2008-20135.1 Penicillins Will Retain Their Niche Despite a Marked Decline in Sales5.2 Tazocin is The Current Market Leader for the Penicillin Class5.3 Can GSKs Augmentin Overcome Generic Competition5.4 Pfizers Unasyn: Third Best Selling Broad-Spectrum Penicillin5.5 Why Will Penicillins Lose Market Share5.6 Leading Companies in the Broad-Spectrum Penicillins Class5.7 Broad Spectrum Penicillins Sales by Region6. The World Market for Fluoroquinolones, 2008-20136.1 An Overview6.2 Increased Competition Will Lower Revenues Among the Fluoroquinolones6.3 Fluoroquinolones Linked With Side Effects6.4 Will J&Js Levaquin Still Dominate The Fluoroquinolones Market After Patent Expiration6.4.1 Levaquin Faces Generic Competition6.4.2 Levaquin Approved for Urinary Tract Infections and Acute Pyelonephritis6.5 Avelox Will Exhibit Steady Growth6.5.1 Head-to-Head Study Finds Avelox to be More Effective in Patients with CAP6.5.2 Avelox Monotherapy as Effective as Combination Therapy in Patients with Severe CAP6.5.3 Avelox Monotherapy as Effective as Multi-Dose Combination Therapy in Patients with cIAI6.5.4 Bayer Warns Doctors on Rare Avelox Side Effects6.6 Cravit Will Gradually Decline in Sales6.7 Leading Companies for the Fluoroquinolones Class, 20096.8 Fluoroquinolones Sales by Region and Country, 20097. The World Market for Macrolides, 2009-20247.1 The Macrolides Will Face Decreased Growth7.1.1 Macrolides: Possible Extra Indications May Expand the Market7.1.2 The Immunomodulatory Effects of Macrolides May Aid Revenue Growth7.1.3 Macrolides May Have a Clinical Use in Other Chronic Lower-Airway Diseases7.2 Abbotts Klacid/Biaxin Leads This Market7.2.1 Klacid/Biaxin Suffers from Generic Competition7.3 Zithromax Faces Negative Growth7.4 Dalacin C: The Third-Leading Brand in Macrolide Class In 20097.5 Leading Companies for Macrolides and Similar Agents, 20097.6 Macrolides and Similar Agents: Sales by Region8. The World Market for Carbapenems, 2009-20248.1 Carbapenems Will See High Growth8.2 Merrem (AstraZeneca) Leads the Market in 20098.2.1 Merrem Received FDA Approval for Complicated Skin InfectionsThe World Antibacterial Treatments Market 2010-2024 Page 4/12
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics8.3 Merck & Cos Zienam is Second-Leading Drug in This Market8.4 Invanz Exhibits Strong Growth8.5 Leading Companies for Other Beta-lactam Antibacterials, 20098.6 Macrolides and Similar Types: Sales by Region9. The World Market for Miscellaneous Antibacterials, 2009-20249.1 Miscellaneous Antibacterials Will See High Growth9.2 Pfizers Blockbuster Zyvox Leads the Market9.2.1 Will Zyvox Overtake Levaquin to Become the New Market Leader in the Antibacterials Sector9.3 Cubists Cubicin Set to Become a Blockbuster9.4 Solodyn Will Show Strong Growth in the Next Decade10. Analysis of Factors That Influence the Global Antibacterials Market10.1 SWOT Analysis of the Antibacterials Market10.2 Drivers and Restraints on Market Growth10.2.1 Market Drivers10.2.2 Market Restraints10.3 To What Extent is the Antibacterials Market Threatened by Generic Substitutes10.3.1 The Threat of Generic Drugs to Original Branded Products10.4 Lifecycle Management Strategies Will Become More Prominent to Protect Soon-to-be-Off-Patent Drugs10.5 Additional Indications for Currently-Available Brands May be an Advantage10.6 Antibacterial Resistance is Due to Increased Infection Rates and Antibacterial Overuse10.6.1 Concerns over Antibacterial Use10.6.2 FDA Measures on Bacterial Resistance10.6.3 Tackling Antibacterial Resistance10.6.4 The Use of Narrow Spectrum Antibacterials is the Best Strategy to Avoid Resistance10.6.5 Antibiotics in the US Carry Warnings Against Overuse10.7 Comparative Studies - a Two Edged Sword10.8 Challenges that Face Antibacterial Pharmaceutical Developers10.9 Future Antibacterial Blockbuster Drug Sales Increasingly Difficult10.10 Antibacterials in the Developing Countries10.11 The Future of the Antibacterials Market - Closing Comments11. Visiongain Interviews with Relevant Experts11.1 Firsthand Interview for Expert Opinion 1: Dr John Philpott-Howard11.1.1 Key Unmet Need11.1.2 About Research and Development11.1.3 Problems with Current Use of Antibiotics11.1.4 Challenges in Development of Antibiotics11.1.5 Technologies and Strategies for the Discovery of New Antibacterial Agents11.1.6 Complexities Involved in Developing Antibiotics11.1.7 Growth Opportunities in the Antibacterial Market11.1.8 Antibacterial Pipeline Developments from the Physicians Perspective11.1.9 Prospects for Replacing Current Antibiotics11.1.10 Prospects for Replacing Cephalosporins11.1.11 Main Regions Offering Growth Potential Worldwide11.2 Firsthand Interview for Expert Opinion 2: Dr Eileen C. McIntyre11.2.1 Unmet Needs in Antimicrobials Market11.2.2 Will Current Antimicrobials be Superseded in the Foreseeable Future11.2.3 Cephalosporins: Looking to the FutureThe World Antibacterial Treatments Market 2010-2024 Page 5/12
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics11.2.4 Prospects for Antimicrobials in the Developing Nations12. The Antibacterial Drug Pipeline12.1 The Cephalosporins Pipeline12.2 Ceftaroline Fosamil (Cerexa)12.3 CXA 101 (Calixa)12.4 The Tetracycline Pipeline12.5 PTK 0796 (Paratek)13. Conclusions13.1 Patent Expiry of Branded Products Will Reduce Growth13.2 Cephalosporins to Continue Their Domination of the Antibacterials Sector in the Near Future13.3 Future Antibacterial Blockbusters13.5 Market Restraints13.6 Opportunities in the Antibacterials Market13.7 Antibacterials Pipeline Overview13.8 The Future of the Antibacterials Market - Closing CommentsList of TablesTable 1.1 The Top 15 Antibacterial Drugs, 2009Table 2.1 Clinically-Important BacteriaTable 3.1 The Global General Systemic Anti-Infectives Market ($m, %), 2009Table 3.2 The Anti-Bacterial Global Market Share ($m) by Therapeutic Class, 2009Table 3.3 Worldwide Sales ($m) of Therapeutic Classes in the Miscellaneous Category, 2009Table 3.4 World Forecasts ($m) for Leading Antibacterial Drugs, by Class, 2009-2015Table 3.5 World Forecasts ($m) for Leading Antibacterial Drugs, by Class, 2016-2024Table 3.6 Worldwide Sales ($m) for Top 15 Antibacterial Drugs, 2009Table 4.1 Worldwide Sales ($m) of Top 15 Products in The Cephalosporins Therapeutic AreaTable 4.2 World Forecasts ($m) for the Cephalosporin Class of Antibacterial Drugs, 2008-2015Table 4.3 World Forecasts ($m) for the Cephalosporin Class of Antibacterial Drugs, 2016-2024Table 4.4 World Market Revenue ($m), 15 Year CAGR (%) and Market Share (%) for Cephalosporin Drugs, 2009-2024Table 4.5 Leading Companies for Cephalosporins ($m), 2009Table 4.6 Cephalosporins Sales ($m) by Region and Country, 2009Table 4.7 Cephalosporins Sales ($m) by Region and Leading Countries in Africa, Asia,Australasia, 2009Table 4.8 Cephalosporins Sales ($m) by Region and Leading Countries in Europe, 2009Table 4.9 Cephalosporins Sales ($m) by Region and Leading Countries in North & South America, 2009Table 5.1 World Sales ($m) for Top 15 Products in The Broad Spectrum Penicillins Therapeutic Area, 2009Table 5.2 World Forecasts ($m) for Broad-Spectrum Penicillins Class, 2008-2015Table 5.3 World Forecasts ($m) for Broad-Spectrum Penicillins Class, 2016-2024Table 5.4 World Market Revenue ($m), 15 Year CAGR (%) and Market Share (%) for Broad-Spectrum Penicillins Drugs, 2009-2024Table 5.5 World Sales ($m) of Leading Companies for Broad Spectrum Penicillins, 2009Table 5.6 Broad Spectrum Penicillins Sales ($m) by Region and Country, 2009Table 5.7 Broad Spectrum Penicillins Sales ($m) for Region and Leading Countries in Africa, Asia, Australasia, 2009Table 5.8 Broad Spectrum Penicillins Sales ($m) by Region and Leading Countries in Europe, 2009Table 5.9 Broad Spectrum Penicillins Sales ($m) by Region and Leading Countries in North & South America, 2009Table 6.1 World Sales ($m) of The Top 15 Drugs in the Fluorquinolones Therapeutic Area, 2009Table 6.2 World Forecasts ($m) for the Fluorquinolones Class of Antibacterial Drugs, 2009-2015Table 6.3 World Forecast ($m) for the Fluorquinolones Class of Antibacterial Drugs, 2016-2024Table 6.4 World Revenue ($m), 15 Year CAGR (%) and Market Share (%) for Fluorquinolone Drugs, 2009-2024The World Antibacterial Treatments Market 2010-2024 Page 6/12
  7. 7. Find Industry reports, Company profilesReportLinker and Market StatisticsTable 6.5 World Sales ($m) of Leading Companies for Fluoroquinolones, 2009Table 6.6 Fluoroquinolones Sales ($m) by Region and Country, 2009Table 6.7 Fluoroquinolones Sales ($m) by Region and Leading Countries in Africa, Asia and Australasia, 2009Table 6.8 Fluoroquinolones Sales ($m) by Region and Leading Countries in Europe, 2009Table 6.9 Fluoroquinolones Sales ($m) by Region and Leading Countries in North & South America, 2009Table 7.1 World Sales ($m) of Top-15 Products in the Macrolides and Similar Types Therapeutic Area, 2009Table 7.2 World Forecasts ($m) for the Macrolides Class of Antibacterial Drugs, 2009-2015Table 7.3 World Forecasts ($m) for Macrolides Class of Antibacterial Drugs, 2016-2024Table 7.4 World Market Revenue ($m), 15 Year CAGR (%) and Market Share (%) for Macrolide Drugs, 2009-2024Table 7.5 World Sales ($m) of Leading Companies for Macrolides and Similar Types, 2009Table 7.6 Sales ($m) by Region and Country for Macrolides and Similar Types, 2009Table 7.7 Sales ($m) by Region and Leading Countries in Africa, Asia and Australasia for Macrolides and Similar Types, 2009Table 7.8 Sales ($m) by Region and Leading Countries in Europe for Macrolides and Similar Types, 2009Table 7.9 Sales ($m) by Region and Leading Countries in North & South America for Macrolides and Similar Types, 2009Table 8.1 World Sales ($m) of Top 15 Products in The Total Other Beta-lactam Antibacterials Therapeutic Area, 2009Table 8.2 World Forecasts ($m) for the Other Beta-lactam Antibacterials Class of Antibacterial Drugs, 2009-2015Table 8.3 World Forecast ($m) for Other Beta-lactam Antibacterials Class of Antibacterial Drugs, 2016-2024Table 8.4 World Market Revenue ($m), 15 Year CAGR (%) And Market Share (%) for Other Beta-lactam Antibacterials Drugs,2009-2024Table 8.5 World Sales ($m) of Leading Companies for Other Beta-lactam Antibacterials, 2009Table 8.6 Sales ($m) by Region and Country for Other Beta-lactam Antibacterials, 2009Table 8.7 Sales ($m) in Africa, Asia, Australasia for Other Beta-lactam Antibacterials, 2009Table 8.8 Sales ($m) by Region and Leading Countries in Europe for Other Beta-lactam Antibacterials, 2009Table 8.9 Sales ($m) by Region and Leading Countries in North & South America for Other Beta-lactam Antibacterials, 2009Table 9.1 World Sales ($m) of Top 15 Products in The Miscellaneous Category, 2009Table 9.2 World Forecasts ($m) for the Miscellaneous Class of Antibacterial Drugs, 2009-2015Table 9.3 World Forecast ($m) for Miscellaneous Class of Antibacterial Drugs, 2016-2024Table 9.4 World Market Revenue ($m), 15 Year CAGR (%) and Market Share (%) for Leading Drugs in Miscellaneous Class,2009-2024Table 10.1 SWOT Chart for the Antibacterials Market, 2009-2024Table 12.1 Pipeline Drugs for Antibacterials (Registered & Pre-reg Phase), 2009Table 12.2 Pipeline Drugs for Antibacterials (Phase III, II), 2009Table 13.1 World Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2009, 2012, 2015, 2018, 2022 & 2024Table 13.2 The Top 10 Antibacterial Drugs on the World Market, by Revenue ($m), 2009List of FiguresFigure 3.1 The Global General Systemic Anti-Infectives Market Shares and Values ($m, %), 2009Figure 3.2 The Anti-Bacterial Global Market Share ($m) by Therapeutic Class, 2009Figure 3.3 The Anti-Bacterial Global Market Share (%) by Therapeutic Class, 2024Figure 3.4 Worldwide Market Share (%) of Therapeutic Classes in The Miscellaneous Category, 2009Figure 3.5 World Forecast ($m) for Systemic Antibacterial Drugs, 2009-2015Figure 3.6 World Forecast ($m) for Systemic Antibacterial Drugs, 2016-2024Figure 3.7 World Forecasts ($m) for Leading Antibacterial Classes, 2009-2015Figure 3.8 World Forecasts ($m) for Leading Antibacterial Classes, 2016-2024Figure 3.9 Worldwide Sales ($m) for Leading Top 15 Antibacterial Drugs, 2009Figure 4.1 Worldwide Sales ($m) for Leading 15 Drugs in The Cephalosporins Therapeutic Area, 2009Figure 4.2 World Forecast ($m) for Cephalosporin Drugs, 2008-2015Figure 4.3 World Forecast ($m) for Cephalosporin Drugs, 2016-2024Figure 4.4 World Forecasts ($m) for Leading Cephalosporin Drugs, 2009-2015The World Antibacterial Treatments Market 2010-2024 Page 7/12
  8. 8. Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 4.5 World Forecasts ($m) for Leading Cephalosporin Drugs, 2016-2024Figure 4.6 World Market Share (%) for Cephalosporins by Leading Drugs, 2009Figure 4.7 World Market Share (%) for Cephalosporins by Leading Drugs, 2024Figure 4.8 World Cephalosporins Share (%) of Sales by Regional Markets, 2009Figure 4.9 Cephalosporin Sales ($m) in Asia, Australasia, Africa (AAA) Region, 2009Figure 4.10 Cephalosporin Sales ($m) in Europe, 2009Figure 4.11 Cephalosporins Market Share (%) in North America, 2009Figure 4.12 Cephalosporin Sales ($m) in Latin America, 2009Figure 5.1 World Sales ($m) of Leading 15 Drugs in The Broad Spectrum Penicillins Therapeutic Area, 2009Figure 5.2 World Forecast ($m) for Broad Spectrum Penicillins Drugs, 2008-2015Figure 5.3 World Forecast ($m) for Broad Spectrum Penicillins Drugs, 2016-2024Figure 5.4 World Forecasts ($m) for Leading Broad Spectrum Penicillins Drugs, 2008-2015Figure 5.5 World Forecasts ($m) for Leading Broad Spectrum Penicillins Drugs, 2016-2024Figure 5.6 World Market Share (%) for Broad Spectrum Penicillins by Leading Drugs, 2009Figure 5.7 World Market Share (%) for Broad Spectrum Penicillins by Leading Drugs, 2024Figure 5.8 Broad Spectrum Penicillins Sales ($m) by Regional Markets, 2009Figure 5.9 Broad Spectrum Penicillins Sales ($m) in Asia, Australasia, Africa (AAA) Region, 2009Figure 5.10 Broad Spectrum Penicillins Sales ($m) in Europe, 2009Figure 5.11 Broad Spectrum Penicillins Sales ($m) in North America, 2009Figure 5.12 Broad Spectrum Penicillins Sales ($m) in Latin America, 2009Figure 6.1 Worldwide Sales ($m) of Leading 15 Drugs in The Fluorquinolone Therapeutic Area, 2009Figure 6.2 World Forecast ($m) for Fluorquinolones Drugs, 2009-2015Figure 6.3 World Forecast ($m) for Fluorquinolones Drugs, 2016-2024Figure 6.4 Forecasts ($m) for Leading Fluorquinolones Drugs, 2008-2015Figure 6.5 Forecasts ($m) for Leading Fluorquinolones Drugs, 2016-2024Figure 6.6 World Market Share (%) for Fluorquinolones by Leading Drugs, 2009Figure 6.7 World Market Share (%) for Fluorquinolones by Leading Drugs, 2024Figure 6.8 Fluoroquinolones Sales ($m) by Regional Markets, 2009Figure 6.9 Fluoroquinolones Sales ($m) in Asia, Australasia, Africa (AAA) Region, 2009Figure 6.10 Fluoroquinolones Sales ($m) in Europe, 2009Figure 6.11 Fluoroquinolones Sales ($m) in North America, 2009Figure 6.12 Fluoroquinolones Sales ($m) in Latin America, 2009Figure 7.1 World Sales ($m) of Leading 15 Drugs in the Macrolides and Similar Types Therapeutic Area, 2009Figure 7.2 World Forecast ($m) for Macrolides and Similar Drugs, 2009-2015Figure 7.3 World Forecast ($m) for Macrolides and Similar Drugs, 2016-2024Figure 7.4 World Forecasts ($m) for Leading Macrolides and Similar Drugs, 2009-2015Figure 7.5 World Forecasts ($m) for Leading Macrolides and Similar Drugs, 2016-2024Figure 7.6 World Market Share (%) for Macrolides and Similar by Leading Drugs, 2009Figure 7.7 World Market Share (%) for Macrolides and Similar by Leading Drugs, 2024Figure 7.8 Macrolides and Similar Types, Sales ($m) by Regional Markets, 2009Figure 7.9 Sales ($m) in Asia, Australasia, Africa (AAA) Region for Macrolides and Similar Types, 2009Figure 7.10 Sales ($m) in Europe for Macrolides and Similar Types, 2009Figure 7.11 Sales ($m) in North America for Macrolides and Similar Types, 2009Figure 7.12 Sales ($m) in Latin America for Macrolides and Similar Types, 2009Figure 8.1 World Sales ($m) of Leading 15 Drugs in The Other Beta-lactam Antibacterial Class, 2009Figure 8.2 World Forecast ($m) for Other Beta-lactam Antibacterial Drugs, 2009-2015Figure 8.3 World Forecast ($m) for Other Beta-lactam Antibacterials Drugs, 2016-2024Figure 8.4 World Forecasts ($m) for Leading Other Beta-lactam Antibacterials Drugs, 2009-2015Figure 8.5 World Forecasts ($m) for Leading Other Beta-lactam Antibacterials Drugs, 2016-2024Figure 8.6 World Market Share (%) for Other Beta-lactam Antibacterials by Leading Drugs, 2009The World Antibacterial Treatments Market 2010-2024 Page 8/12
  9. 9. Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 8.7 World Market Share (%) for Other Beta-lactam Antibacterials by Leading Drugs, 2024Figure 8.8 Sales ($m) by Regional Markets for Other Beta-lactam Antibacterials, 2009Figure 8.9 Sales ($m) in Asia, Australasia, Africa (AAA) Region for Other Beta-lactam Antibacterials, 2009Figure 8.10 Sales ($m) in Europe for Other Beta-lactam Antibacterials, 2009Figure 8.11 Sales ($m) in North America for Other Beta-lactam Antibacterials, 2009Figure 8.12 Sales ($m) in Latin America for Other Beta-lactam Antibacterials, 2009Figure 9.1 World Sales ($m) of Top 15 Products in The Miscellaneous Category, 2009Figure 9.2 World Forecasts ($m) for Miscellaneous Class Antibacterial Drugs, 2008-2015Figure 9.3 World Forecasts ($m) for Miscellaneous Class Antibacterial Drugs, 2016-2024Figure 9.4 Forecasts ($m) for Leading Miscellaneous Class Antibacterial Drugs, 2009-2015Figure 9.5 Forecasts ($m) for Leading Miscellaneous Class Antibacterial Drugs, 2016-2024Figure 9.6 World Market Share (%) for Miscellaneous Class by Leading Drugs, 2009Figure 9.7 World Market Share (%) for Miscellaneous Class by Leading Drugs, 2024Figure 13.1 Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2009-2024Companies ListedAbbottActavisAlembicAndrxArrow GeneriquesAstellasAstraZenecaBaxterBayerBedford LaboratoriesBiofarmaBristol-Myers SquibbCiproCubistDaiichi SankyoDainippon SumitomoDr. Reddys LaboratoriesElanEli LillyEuropean Medicines Agency (EMEA)EMSFood and Drug Administration (FDA)GD.SZ.Zhijun Pharm (China)GD.ZH.YIBANG PHAR (China)GeneriquesGenevaGlaxoSmithKline (GSK)Hikma RoemmersHLJ Haerbin Pharm.JiangsuJiangsu YangZijiangJohnson & Johnson (J&J)KrkaThe World Antibacterial Treatments Market 2010-2024 Page 9/12
  10. 10. Find Industry reports, Company profilesReportLinker and Market StatisticsLek (part of the Novartis group)LupinMaruhoMedicisMeiji SeikaMenariniMerck & Co.MIP GroupMylanNestleNovartisOrchidPfizerPliva (now part of Barr)Ranbaxy (India)RatiopharmRocheSandozSankyo (now Daiichi Sankyo, Japan)sanofi-aventisSawai Pharmaceutical Co., Ltd.SC.CQ.Qingyutang (China)Schering-PloughShandong Ruiyang (China)Shanghai Asia PioneerShenzhen Haibin (China)Shionogi & Co., Ltd.SX.Qiany Uan Pharm (China)SX.Weiqida Pharm (China)TaishoTakedaTevaWockhardtWyethYangZijiangYuhanZJ.Yiyao Xinchang (China)The World Antibacterial Treatments Market 2010-2024 Page 10/12
  11. 11. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. The World Antibacterial Treatments Market 2010-2024 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 417.21 Quantity: _____ Department License--USD 4 834.42 Quantity: _____ Site License--USD 8 046.71 Quantity: _____ Corporate License--USD 11 265.95 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________The World Antibacterial Treatments Market 2010-2024 Page 11/12
  12. 12. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93The World Antibacterial Treatments Market 2010-2024 Page 12/12

×